Current and emerging biological therapies for Chronic rhinosinusitis with nasal polyps with type 2 inflammation
INTRODUCTION: Chronic rhinosinusitis with nasal polyps (CRSwNP), especially CRSwNP with type 2 inflammation, remains the most difficult-to-treat subtype with high prevalence worldwide. The emergence of biologics has the potential to fulfill the unmet medical needs of patients with CRSwNP driven by type 2 inflammation.
AREAS COVERED: A current review of the literature was performed to overview current and emerging biological therapies in the treatment of CRSwNP.
EXPERT OPINION: In an era of precision medicine, biologics have been given expectations to provide customized therapies to patients with CRSwNP, particularly those with refractory CRSwNP. Large clinical trials and real-world experiences are both essential for the application of biologics. Moreover, to make biological therapy more tailored to patients, an in-depth understanding of the different mechanisms of biologics, further elucidating the relationship between biologics and conventional medical and surgical treatments, and identifying predictive biomarkers warrant thorough investigations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Expert opinion on investigational drugs - 32(2023), 10 vom: 19. Juli, Seite 909-919 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jin, Zeyi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological Products |
|---|
| Anmerkungen: |
Date Completed 07.11.2023 Date Revised 07.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/13543784.2023.2273502 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363477160 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363477160 | ||
| 003 | DE-627 | ||
| 005 | 20231226093430.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13543784.2023.2273502 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1211.xml |
| 035 | |a (DE-627)NLM363477160 | ||
| 035 | |a (NLM)37855222 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jin, Zeyi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current and emerging biological therapies for Chronic rhinosinusitis with nasal polyps with type 2 inflammation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.11.2023 | ||
| 500 | |a Date Revised 07.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Chronic rhinosinusitis with nasal polyps (CRSwNP), especially CRSwNP with type 2 inflammation, remains the most difficult-to-treat subtype with high prevalence worldwide. The emergence of biologics has the potential to fulfill the unmet medical needs of patients with CRSwNP driven by type 2 inflammation | ||
| 520 | |a AREAS COVERED: A current review of the literature was performed to overview current and emerging biological therapies in the treatment of CRSwNP | ||
| 520 | |a EXPERT OPINION: In an era of precision medicine, biologics have been given expectations to provide customized therapies to patients with CRSwNP, particularly those with refractory CRSwNP. Large clinical trials and real-world experiences are both essential for the application of biologics. Moreover, to make biological therapy more tailored to patients, an in-depth understanding of the different mechanisms of biologics, further elucidating the relationship between biologics and conventional medical and surgical treatments, and identifying predictive biomarkers warrant thorough investigations | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biologics | |
| 650 | 4 | |a chronic rhinosinusitis with nasal polyps (CRSwNP) | |
| 650 | 4 | |a monoclonal antibody | |
| 650 | 4 | |a refractory | |
| 650 | 4 | |a type 2 inflammation | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 700 | 1 | |a Yan, Bing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Luo |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chengshuo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on investigational drugs |d 1995 |g 32(2023), 10 vom: 19. Juli, Seite 909-919 |w (DE-627)NLM093775326 |x 1744-7658 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2023 |g number:10 |g day:19 |g month:07 |g pages:909-919 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13543784.2023.2273502 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2023 |e 10 |b 19 |c 07 |h 909-919 | ||